10\m=-\12 m forskolin after a 3 min exposure time. Maximal stimulation was observed with 10\m=-\12m forskolin. However, the dose-response curve to forskolin was not parallel to that given by TSH, the slope of the ascending limb being much greater. It has been suggested that stimulation of \g=b\-naphthylamidaseactivity in the CBA is via cAMP. We report that dibutyryl cAMP at doses from 10\m=-\16m to 10\m=-\11 m produces a bell-shaped dose-response curve with a very broad peak response, again not parallel to that produced by TSH (Lindner et al. 1978) and con¬ traction of guinea pig papillary muscles. Metzger & Lindner (1981) however, were the first to demon¬ strate adenylate cyclase activation by forskolin in rabbit heart slices. Subsequently forskolin has been shown to be a potent stimulator of adenylate cyclase in many other tissues including guinea pig (Fradkin et al. 1982) and canine or bovine (Van Sande et al. 1982 Totsuka et al. 1983) thyroid membrane and slice preparations.
In the present study we report that forskolin activates ß-naphthylamidase in guinea pig thyroid sections, using the ultrasensitive cytochemical bioassay for thyroid stimulators (Chayen et Stimulation of ß-naphthylamidase activity in guinea pig thyroid sections by IO"14 to 10"11 M forskolin, as assessed by a cytochemical bioassay using two différend thyroid glands 1 (A) and 2 ( ). The forskolin dilutions were made in 'carrier medium' from a starting solution of 10 mM forskolin dissolved in 95% ethanol. Sections were also exposed to 1.6 x "8 M ethanol shown as ethanol controls for thyroids 1 and 2. In both assays an exposure time of 3 min was used.
The mean integrated extinction was determined for 4 sections for each dilution except where indicated. Each experimental point represents the mean ± SD for the given number of sections. In addition sections from thyroid 1 were exposed to doses of TSH from 10"5 to 10"2 mU/1 ( ). (Ealey etal. 1981) . Fig. 1 shows the dose-response curves to forskolin measured in 2 separate assays, each using a dif¬ ferent thyroid gland and also the dose-response curve produced by TSH acting on sections from thyroid 1 in assay (1). Clearly, the ascending limb of the dose-response curve to forskolin was not paral¬ lel to that for TSH. A relatively sharp increase in naphthylamidase activity, from unstimulated con¬ trol to maximal levels, occurred over the dose range 10~13 and 10~12M forskolin, in both separate assays, whereas with TSH, as described previously (Ealey et al. 1981) , the corresponding increase was observed over a wider dose range (10~5 to 10-3 mU/ml). present at the forskolin concentrations used (i.e.
1.6
10"12M to 1.6 x 10"8M ethanol) and the naphthylamidase activity was not significantly dif¬ ferent from that measured in the control sections ('carrier medium' alone).
With a section exposure time of 3 min, doses of the order of 10~3 mU/l TSH produce a maximum increase in naphthylamidase activity (Ealey et al. 1981) , and this maximal mean integrated extinc¬ tion was also seen with 10~12M forskolin (Fig. 1) . (Fig. 2 ) or at other dilutions tested (1:102-1:1012; not shown). In contrast to its ability to inhibit thyrotrophin, 11E8 was found to be without effect on the stimulation produced by an equipotent dose of forskolin (Fig. 2) .
It has been suggested that forskolin activation is mediated by cAMP. This supposition is supported by our observation that increased ß-naphthylamidase activity was obtained when thyroid sec¬ tions were exposed to dibutyryl cAMP (Fig. 3) . However, when responses are compared for a range of doses of dibutyryl cAMP (ÍO^16-10"11 M) it is clear that the bell-shaped dose-response curve obtained (Fig. 3) differs significantly from that observed with TSH and forskolin (Fig. 1) (Totsuka et al. 1983) , and other thyroid preparations (Fradkin et al. 1982; Van Sande et al. 1982 , once again demon¬ strating the ultrasensitivity of this CBA (Ealey et al. 1981 ).
Although the sequence of intracellular events operative in the CBA in response to thyrotrophin is not known, there has been a suggestion that cAMP acts as an intermediary (Petersen et al. 1975) . Our observation that forskolin, an apparently ubiquit¬ ous adenylate cyclase stimulator , also stimulates guinea pig thyroid sections in the CBA would seem to support this view, since it has been proposed that the drug can be used as a probe for cAMP me¬ diated effects in the thyroid (Van Sande et al. 1983) . Moreover, an increase in naphthylamidase activity was seen with dibutyryl cAMP However, the slopes of the dose-response curves to TSH, forskolin and dibutyryl cAMP showed significant differences which presumably reflect differences in their mechanisms of action in the CBA. The dis-crepancies between the slopes of the dose-response curves to dibutyryl cAMP and forskolin were parti¬ cularly marked. It is possible therefore, that as has recently been concluded from studies on iodide efflux (Weiss et al. 1984) , although forskolin stimu¬ lates cAMP accumulation in the thyroid, its effects on naphthylamidase may be at least in part due to independent events.
The site of action of forskolin on the cyclase complex is at present uncertain, although there is evidence that it acts through a unique mechanism involving both direct activation of the enzyme and facilitation or potentiation of the modulation of enzyme activity either by receptors or the guanyl nucleotide-binding subunits, or both of these . Van Sande et al. (1982, 1983) (Valente et al. 1982) . Moreover, in the CBA it has been shown to discriminate between TSH and TSAb stimula¬ tion, suggesting that it is directed against a discrete site on the receptor which is obligatory for TSH (Ealey et al. 1984; Kohn et al., in press). The failure of 11E8 to inhibit the response to forskolin, whilst abolishing the response to an equipotent dose of TSH (Fig. 2) , is further evidence that forskolin action is not mediated by the TSH receptor on the thyroid cell surface.
